Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Liabilities: 2023-2025

Historic Total Liabilities for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $23.2 million.

  • BioLineRx's Total Liabilities fell 54.17% to $23.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $140.7 million, marking a year-over-year decrease of 15.63%. This contributed to the annual value of $25.4 million for FY2024, which is 49.81% down from last year.
  • As of Q2 2025, BioLineRx's Total Liabilities stood at $23.2 million, which was up 2.42% from $22.6 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Total Liabilities peaked at $50.7 million during Q4 2023, and registered a low of $22.6 million during Q1 2025.
  • Its 3-year average for Total Liabilities is $36.3 million, with a median of $38.2 million in 2023.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 33.61% in 2024, then slumped by 54.17% in 2025.
  • Quarterly analysis of 3 years shows BioLineRx's Total Liabilities stood at $50.7 million in 2023, then crashed by 49.81% to $25.4 million in 2024, then slumped by 54.17% to $23.2 million in 2025.
  • Its Total Liabilities was $23.2 million in Q2 2025, compared to $22.6 million in Q1 2025 and $25.4 million in Q4 2024.